Company overview
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue?our mission?at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
In compliance with applicable State regulatory authorities, COVID-19 vaccination is mandatory for all MSK staff. Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 (i.e., one dose of a single dose vaccine or a final dose of a multi-dose vaccine series). Exceptions from the COVID-19 vaccine requirement are permitted for those who request and receive an approved medical or fully remote exemption. Requests for medical exemption can take up to two weeks to review. Vaccination or an approved medical exemption is required to start work.
*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.
Note: Individuals are eligible to receive a COVID-19 booster two months after completion of a primary vaccination series for COVID-19. Because vaccine-induced immunity can wane over time, MSK continues to strongly urge all staff to get a COVID-19 booster as soon as they become eligible to maintain their protective immunity for a longer period.
Job details
Myeloma Service
Division of Hematologic Malignancies, Department of Medicine
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) is one of the world’s premier cancer centers, committed to exceptional patient care, leading-edge research, and superb educational programs. The blending of research with patient care is at the heart of everything we do. The institution is a comprehensive cancer center whose purposes are the treatment and control of cancer, the advancement of biomedical knowledge through laboratory and clinical research, and the training of scientists, physicians and other health care workers.
The largest of MSK’s clinical departments, the Department of Medicine (DoM) encompasses experts in solid tumor oncology, hematologic malignancies, subspecialty medicine and supportive and acute care services. Offering a range of services both in multiple sites in New York City and at their suburban outpatient locations in our Regional Care Network (RCN), DoM physicians oversee the care of the whole patient. The RCN serves the areas surrounding Manhattan and extends from Southern New Jersey to Eastern Long Island and brings the same high level of expertise, clinical care, and access to clinical trial protocols that are available at our main campus in New York City.
The Myeloma Service in the Department of Medicine at MSK is seeking a full-time Lab Investigator or Clinical Investigator at the assistant or associate attending level for clinical service, teaching, and research. Highly motivated and collaborative candidates with research interests in genomics, geriatric myeloma, immunotherapies, and/or healthcare disparities are strongly encouraged to apply. Under new leadership, the Myeloma Service has a strong interest in delivering multidisciplinary care for patients with all myeloma entities and furthering a comprehensive research portfolio. Our 9 full-time oncologists see patients at different stages of their disease management, coordinating their care and developing comprehensive and innovative strategies using conventional and investigational treatments, including immune-based, targeted and cell therapies. The service supports a wide range of clinical and translational research, with established collaborations with other clinical services and research laboratories within MSK as well as external collaborators, and a strong track record of publications in top tier journals of medicine, oncology, and hematology. Candidates must be board certified or board eligible in medical oncology and hematology.
Service Page:
Multiple Myeloma
Please click on the link to apply; be sure to include a CV, career statement and any additional relevant information.
For further faculty recruitment opportunities, please visit MSKCC Faculty Recruitment Portal.